HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

HIV research programs have been halted, and many treatment clinics are still closed, despite a waiver for “life-saving” ...

alternative drug to ensure the continued profitability of Truvada. The drug also featured at the centre of legal proceedings between the US government and the company over patent ownership ...

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

The announcement comes swiftly after the drug achieved significant milestones ... compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the trials ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

LILY Phillips has revealed she is taking HIV protection drug PrEP ahead of her next sex challenge. But viewers have claimed ...

US appeals court reinstates pause on generic version of Novartis' Entresto ... patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...

This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.

Please be advised that today's conference is being recorded. I would now like to hand the conference over to Sally Schwartz, Vice President of Investor Relations. Hello everyone and welcome to our ...

Generic Eng Standalone December 2023 Net Sales at Rs 58.97 crore, down 5.09% Y-o-Y Mar 01 2024 01:54 PM Generic Eng Standalone September 2023 Net Sales at Rs 37.20 crore, down 30.48% Y-o-Y Dec 04 ...